Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQ Birch dose-ranging placebo-controlled study in birch pollen allergic rhinoconjunctivitis
2015-000984-15Phase 2Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- May 2015
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of depigoid birch in seasonal allergic rhinitis (SAR) (7 arms), sponsored by Allergy Therapeutics PLC. Primary endpoint: Change from baseline to post-treatment in total symptom score following conjunctival provocation test. Started May 2015; status: completed.
02
Drugs
depigoid birch
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2015-000984-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000984-15.